Concepedia

Kevin D. Burris

KD

29

Publications

2.4K

Citations

21

H-Index

1987

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Otsuka (Japan)

Vanderbilt University

Eli Lilly (United States)

Palatin Technologies (United States)

Kevin D. Burris is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and drug discovery.

Top concepts

Publications per year

1987–2019

29

Publications

29

Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors

Kevin D. Burris, Thaddeus F. Molski, Cen Xu et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 914 citations

Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis.

Elaine Sanders‐Bush, Kevin D. Burris, Karen M. Knoth · Journal of Pharmacology and Experimental Therapeutics · 1988 · 155 citations

Expression of the Human 5-Hydroxytryptamine1A Receptor in Sf9 Cells

Paul Butkerait, Yejia Zheng, Hazem Hallak et al. · Journal of Biological Chemistry · 1995 · 154 citations · Full text

Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies

Arlene Stark, Shaun Jordan, Kelly A. Allers et al. · Psychopharmacology · 2006 · 143 citations

, , +13

Mechanism of Action of Aripiprazole Predicts Clinical Efficacy and a Favourable Side-Effect Profile

Tsuyoshi Hirose, Yasufumi Uwahodo, Sakiko Yamada et al. · Journal of Psychopharmacology · 2004 · 131 citations

Rows per page

1–5 of 29